Envoy Medical Highlights First Clinical Data Presentations from Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant

Positive Initial 6-Month Data from First 10 Patients and Improvements in Speech Understanding and Quality of Life Scores Presented; Additional Presentations Scheduled in Early May Details to be Discussed During Fireside Chat on April 29, 2026 at 4:30 pm ET White Bear Lake, Minnesota--(Newsfile Corp. - April 28, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the first podium presentations of clinical data from the first stage of its pivotal clinical study of the investigational Acclaim® cochlear implant, a first-of-its-kind, fully implanted cochlear implant system. The Company will host a Fireside Chat with Dr. Theodore McRackan, MD, MSCR and Dr. Elizabeth Camposeo, AuD from the Medical University of South Carolina (MUSC) on Wednesday April 29, 2026 at 4:30 pm ET to review the data and its clinical implications.